Clinical Research Directory
Browse clinical research sites, groups, and studies.
Semaglutide and Physical Activity for Obesity and Multimorbidity
Sponsor: Hvidovre University Hospital
Summary
The aim of this observational study is to explore and describe changes in cardiometabolic health, physical activity, physical capacity, and wellbeing during interdisciplinary Semaglutide-based weight loss treatment in patients with severe obesity and multimorbidity. This study is explorative and therefore does not include hypothesis testing.
Official title: Semaglutide and Physical Activity for Obesity and Multimorbidity: Co-designing Healthy Healthcare
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
35
Start Date
2024-02-20
Completion Date
2026-11
Last Updated
2024-12-12
Healthy Volunteers
No
Conditions
Interventions
Semaglutide 2.4 mg, total diet replacement, behavioural intervention
Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.
Locations (1)
Copenhagen University Hospital, Hvidovre
Hvidovre, Capital Region, Denmark